Verteporfin photodynamic therapy for anterior segment neovascularization secondary to ischaemic central retinal vein occlusion

Parodi, Maurizio Battaglia; Iacono, Pierluigi; Ravalico, Giuseppe

doi:10.1111/j.1442-9071.2008.01723.x

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Photodynamic Therapymentioning

confidence: 99%

“…Photodynamic therapy (PDT) with verteporfin as a photosensitizer was evaluated for the treatment of anterior segment neovascularization secondary to iCRVO in an RCT and in a prospective interventional study (227,229) . The laser energy in PDT was directed to the anterior chamber angle and the iris using a Goldmann three-mirror contact lens (227,229) . In the RCT, patients with iCRVO, defined by the presence of ≥ 10 DA of capillary non-perfusion on FFA and reduced b-wave amplitude on ERG, were randomized to PDT (n=17), standard PRP (n=19) and selective PRP (n=20), the latter being performed only if iris/angle neovascularization showed progression on weekly follow-up (229) .…”

Section: Photodynamic Therapymentioning

confidence: 99%

“…A prospective interventional study including ten patients with iCRVO and iris/angle neovascularization suggested that PDT can partially obliterate anterior segment neovascularization (227) .…”

Section: Photodynamic Therapymentioning

confidence: 99%

See 2 more Smart Citations

Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion

Khayat

Williams

Lois

2018

Survey of Ophthalmology

View full text Add to dashboard Cite

Retinal vein occlusion (RVO)-including central RVO, branch RVO, and hemicentral and hemispheric RVO-is the second most common vascular cause of visual loss, surpassed only by diabetic retinopathy. The presence and extent of retinal ischemia in RVO is associated with a worse prognosis. On this basis, most previously conducted studies considered ischemic retinal vein occlusion (iRVO) and non-iRVO as separate entities based on set thresholds of existing retinal ischemia as determined by fundus fluorescein angiography. Other diagnostic technologies have been used specifically in the differentiation of ischemic central retinal vein occlusion and nonischemic central retinal vein occlusion. To date, there is no fully accepted definition for iRVO. Some clinicians and researchers may favor establishing a clear differentiation between these forms of RVO; others may prefer not to consider iRVO as a separate entity. Whatever the case, retinal ischemia in RVO confers a higher risk of visual loss and neovascular complications; thus, it should be determined as accurately as possible in patients with this disease and be considered in clinical and experimental studies. Most recently conducted clinical trials evaluating new treatments for macular edema secondary to RVO included none or only few patients with iRVO based on previous definitions (i.e., few patients with sizeable areas of retinal ischemia were recruited in these trials), and thus it is unclear whether the results observed in recruited patients could be extrapolated to those with retinal ischemia. There has been scant research aiming at developing and/or testing treatments for retinal ischemia, as well as to prevent new vessel formation as a result of RVO. We provide a detailed review of the knowledge gathered over the years on iRVO, from controversies on its definition and diagnosis to the understanding of its epidemiology, risk factors and pathogenesis, the structural and functional effects of this disease in the eye and its complications, natural history, and outcomes after treatment. In each section, the definition of iRVO used is given so, independently of whether iRVO is considered a separate clinical entity or a more severe end of the spectrum of RVO, the information will be useful to clinicians to determine patient's risk, guide therapeutic decisions, and counsel patients and for researchers to design future studies.

show abstract

Section: Photodynamic Therapymentioning

confidence: 99%

Section: Photodynamic Therapymentioning

confidence: 99%

See 1 more Smart Citation

Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion

Khayat

Williams

Lois

2018

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…There has recently been one report based on ten eyes with ischemic CRVO, treated with this mode of therapy [ 355 ]. The authors claimed that it can partially obliterate anterior segment neovascularization in eyes affected by ischemic CRVO and prevent them from evolving to advanced stages of neovascular glaucoma, but is not effective in cases with complete angle synechial closure.…”

Section: Verteporfi N Photodynamic Therapymentioning

confidence: 98%

Central Retinal Vein Occlusion

Hayreh

2014

Ocular Vascular Occlusive Disorders

View full text Add to dashboard Cite

show abstract

Apport des anti-VEGF dans le traitement de la néovascularisation du segment antérieur compliquant les occlusions veineuses rétiniennes

Kabesha

Glacet–Bernard

Rostaqui

et al. 2015

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Verteporfin photodynamic therapy for anterior segment neovascularization secondary to ischaemic central retinal vein occlusion

Abstract: Our results show that PDT with verteporfin can partially obliterate ASNVs in eyes affected by ischaemic CRVO preventing from the evolution towards advanced stages of neovascular glaucoma, but is not effective in cases with complete angle synechial closure.

Cited by 4 publications

References 34 publications

Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion

Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion

Central Retinal Vein Occlusion

Apport des anti-VEGF dans le traitement de la néovascularisation du segment antérieur compliquant les occlusions veineuses rétiniennes

Contact Info

Product

Resources

About